Posted by The literature provides a large range of information on the manufacturing of CD-based materials for pulmonary delivery, the characterization of the obtained formulations, their suitability for lung deposition, the pharmacokinetics of the drugs when loaded in a particular formulation, and the resulting biological effects, yet the challenges of their clinical translation remain to be addressed.
In this review, we presented an overview of the different formulations containing CDs and intended for pulmonary delivery. Emphasis was placed on the role of these host molecules in the formulation, starting with their ability to encapsulate active compounds or to be used as excipients and lastly as active ingredients themselves. Finally, this review highlights a number of research gaps that could be addressed in the future to benefit from the properties of CDs in pulmonary delivery.
It is of special interest that CDs as active agents can be used to treat diseases related to surfactant dysfunction due to the increase in its cholesterol content. Literature proved that surfactant function was restored using methylated-CDs, but no in vivo studies where CDs were administered to living animals were conducted.
Petra Gerges, Miriana Kfoury, David Landy, Sophie Fourmentin, Hélène Greige-Gerges (2025) Cyclodextrin-based materials for pulmonary delivery: Insights and challenges. Carbohydrate Polymers 363, 123712.
https://doi.org/10.1016/j.carbpol.2025.123712